Harnessing Type I Interferon-mediated Immunity to Target Malignant Brain Tumors

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jun 12

PMID 37304294

Authors

Juhee Lim

In Kang

Jeongwoo La

Keun Bon Ku

Byeong Hoon Kang

Yumin Kim

Won Hyung Park

Heung Kyu Lee

Affiliations

Soon will be listed here.

Abstract

Type I interferons have long been appreciated as a cytokine family that regulates antiviral immunity. Recently, their role in eliciting antitumor immune responses has gained increasing attention. Within the immunosuppressive tumor microenvironment (TME), interferons stimulate tumor-infiltrating lymphocytes to promote immune clearance and essentially reshape a "cold" TME into an immune-activating "hot" TME. In this review, we focus on gliomas, with an emphasis on malignant glioblastoma, as these brain tumors possess a highly invasive and heterogenous brain TME. We address how type I interferons regulate antitumor immune responses against malignant gliomas and reshape the overall immune landscape of the brain TME. Furthermore, we discuss how these findings can translate into future immunotherapies targeting brain tumors in general.

Citing Articles

Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment.

Berezovsky A, Nuga O, Datta I, Bergman K, Sabedot T, Gurdziel K PLoS One. 2025; 20(2):e0315171.

PMID: 39919036 PMC: 11805374. DOI: 10.1371/journal.pone.0315171.

Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma.

Leshem R, Sefton K, Wong C, Lin I, Isaac D, Niepel M J Immunother Cancer. 2025; 13(1).

PMID: 39870492 PMC: 11772928. DOI: 10.1136/jitc-2024-010683.

An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.

Stergiopoulos G, Concilio S, Galanis E Curr Treat Options Oncol. 2024; 25(7):952-991.

PMID: 38896326 PMC: 11878440. DOI: 10.1007/s11864-024-01211-6.

Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment.

Ma C, Yang C, Peng A, Sun T, Ji X, Mi J Mol Cancer. 2023; 22(1):170.

PMID: 37833788 PMC: 10571470. DOI: 10.1186/s12943-023-01876-x.

References

Tay R, Richardson E, Toh H . Revisiting the role of CD4 T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2020; 28(1-2):5-17. PMC: 7886651. DOI: 10.1038/s41417-020-0183-x. View

Zemek R, Chin W, Fear V, Wylie B, Casey T, Forbes C . Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice. Nat Commun. 2022; 13(1):4895. PMC: 9390963. DOI: 10.1038/s41467-022-32567-8. View

de Palma M, Mazzieri R, Politi L, Pucci F, Zonari E, Sitia G . Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell. 2008; 14(4):299-311. DOI: 10.1016/j.ccr.2008.09.004. View

Kwart D, He J, Srivatsan S, Lett C, Golubov J, Oswald E . Cancer cell-derived type I interferons instruct tumor monocyte polarization. Cell Rep. 2022; 41(10):111769. DOI: 10.1016/j.celrep.2022.111769. View

Katlinski K, Gui J, Katlinskaya Y, Ortiz A, Chakraborty R, Bhattacharya S . Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell. 2017; 31(2):194-207. PMC: 5313042. DOI: 10.1016/j.ccell.2017.01.004. View

Baruch K, Deczkowska A, David E, Castellano J, Miller O, Kertser A . Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science. 2014; 346(6205):89-93. PMC: 4869326. DOI: 10.1126/science.1252945. View

von Locquenghien M, Rozalen C, Celia-Terrassa T . Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J Clin Invest. 2021; 131(1). PMC: 7773346. DOI: 10.1172/JCI143296. View

Abedalthagafi M, Barakeh D, Foshay K . Immunogenetics of glioblastoma: the future of personalized patient management. NPJ Precis Oncol. 2018; 2:27. PMC: 6279755. DOI: 10.1038/s41698-018-0070-1. View

Hashimoto H, Ueda R, Narumi K, Heike Y, Yoshida T, Aoki K . Type I IFN gene delivery suppresses regulatory T cells within tumors. Cancer Gene Ther. 2014; 21(12):532-41. DOI: 10.1038/cgt.2014.60. View

10.

Lee-Chang C . Understanding the relationship between gliomas and T cells: Paving the way for effective immunotherapy. Neuro Oncol. 2022; 24(10):1658-1659. PMC: 9527519. DOI: 10.1093/neuonc/noac152. View

11.

Chen W, Teo J, Yau S, Wong M, Lok C, Che C . Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8 T cell exhaustion and curtails anti-PD-1 efficacy. Cell Rep. 2022; 41(7):111647. DOI: 10.1016/j.celrep.2022.111647. View

12.

Borden E . Interferons α and β in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov. 2019; 18(3):219-234. DOI: 10.1038/s41573-018-0011-2. View

13.

Magen A, Nie J, Ciucci T, Tamoutounour S, Zhao Y, Mehta M . Single-Cell Profiling Defines Transcriptomic Signatures Specific to Tumor-Reactive versus Virus-Responsive CD4 T Cells. Cell Rep. 2019; 29(10):3019-3032.e6. PMC: 6934378. DOI: 10.1016/j.celrep.2019.10.131. View

14.

Blomberg E, Silginer M, Roth P, Weller M . Differential roles of type I interferon signaling in tumor versus host cells in experimental glioma models. Transl Oncol. 2022; 28:101607. PMC: 9800198. DOI: 10.1016/j.tranon.2022.101607. View

15.

Lopez-Soto A, Gonzalez S, Folgueras A . IFN Signaling and ICB Resistance: Time is on Tumor's Side. Trends Cancer. 2017; 3(3):161-163. DOI: 10.1016/j.trecan.2017.01.004. View

16.

Sumida T, Dulberg S, Schupp J, Lincoln M, Stillwell H, Axisa P . Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat Immunol. 2022; 23(4):632-642. PMC: 8989655. DOI: 10.1038/s41590-022-01152-y. View

17.

Lim M, Xia Y, Bettegowda C, Weller M . Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018; 15(7):422-442. DOI: 10.1038/s41571-018-0003-5. View

18.

Liao J, Luan Y, Ren Z, Liu X, Xue D, Xu H . Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. Cancer Immunol Res. 2017; 5(7):560-570. PMC: 5510552. DOI: 10.1158/2326-6066.CIR-16-0221. View

19.

Amoozgar Z, Kloepper J, Ren J, Tay R, Kazer S, Kiner E . Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021; 12(1):2582. PMC: 8113440. DOI: 10.1038/s41467-021-22885-8. View

20.

Shekarian T, Zinner C, Bartoszek E, Duchemin W, Wachnowicz A, Hogan S . Immunotherapy of glioblastoma explants induces interferon-γ responses and spatial immune cell rearrangements in tumor center, but not periphery. Sci Adv. 2022; 8(26):eabn9440. PMC: 10883360. DOI: 10.1126/sciadv.abn9440. View